A review of oncology literature compiled by Giuseppe Curigliano, Division of Medical Oncology, IEO, Milan, Italy

HER2 and Chromosome 17 Effect on Patient Outcome in the N9831 Adjuvant Trastuzumab Trial
E. Perez et al. JCO October 1, 2010 vol. 28 no. 28 4307-4315

IHC or FISH HER2 testing is appropriate for patient selection for adjuvant trastuzumab therapy. Trastuzumab benefit seemed independent of HER2/centromere 17 ratio and chromosome 17 copy number.

Abstract: The Journal of Clinical Oncology

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Bang YL et al. Lancet. 2010 Aug 28;376(9742):687-97

Trastuzumab in combination with chemotherapy can be considered as a new standard option for patients with HER2-positive advanced gastric or gastro-oesophageal junction cancer

Abstract: The Lancet

The Nobel Prize in Physiology or Medicine 2010 was awarded to Robert G. Edwards "for the development of in vitro fertilization"

Read: Early stages of fertilization in vitro of human oocytes matured in vitro Edwards RG et al. Nature. 1969 Feb 15;221(5181):632-5

Birth after the reimplantation of a human embryo. Edwards RG et al. Lancet. 1978 Aug 12;2(8085):366.